Opinion: U.S. Organizations Could Have Included ‘Reasonable’ Pricing Clause for Zolgensma
The National Institute of Health and nonprofits that backed the development of Novartis' spinal muscular atrophy (SMA)… Read more
HEOR Feature
Featured
Wynne Health Group’s LaRosa Talks Drug Pricing Efforts in Washington
Josh LaRosa, Wynne Health Group policy associate, recently discussed the potential impact a number of drug pricing initiatives coming out of… Read more
Article Spotlights ICER Summit on Cure Valuation
A recent article published on BioWorld spotlights the Institute for Clinical and Economic Review's (ICER) recent summit on drug valuation, and how… Read more
Dreyer Talks Real-World Evidence
IQVIA CSO and Global Chief of Scientific Affairs Nancy Dreyer recently discussed her DIA presentation on real-world evidence (RWE), and when it's… Read more
